RARITAN, N.J., May 16, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO ® (rivaroxaban) ...

Please provide your email address to receive an email when new articles are posted on . In a cohort of patients with renal impairment who underwent peripheral revascularization, rivaroxaban reduced ...

Following a lower limb revascularization, rivaroxaban (Xarelto; Bayer/Janssen) added to daily aspirin is better than aspirin alone for reducing the risk of first and total limb and CV events, a ...

Lower extremity revascularization in nursing home residents in the USA is associated with a high mortality and little gain of function at 1 year after surgery. These findings come from a retrospective ...

The US Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the direct oral anticoagulant rivaroxaban (Xarelto) to include patients who have ...

Please provide your email address to receive an email when new articles are posted on . In the VOYAGER PAD trial, patients with symptomatic peripheral artery disease who underwent lower-extremity ...

RARITAN, N.J., Aug. 24, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded ...

Lower extremity artery disease (LEAD) is a leading cause of morbidity and mortality worldwide, affecting hundreds of millions of people. On top of that, LEAD also represents a prominent marker of ...

Lower extremity artery disease (LEAD) is a leading cause of morbidity and mortality worldwide, affecting hundreds of millions of people. On top of that, LEAD also represents a prominent marker of ...

RARITAN, N.J., May 16, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO (R) (rivaroxaban) ...